Lupin eyes share of $48 mn market with anti-infection capsule launch in US

Drug major Lupin on Friday said it has launched Flucytosine capsules, used to treat serious infections, in the American market.

The company has launched its generic product in the strengths of 250 mg and 500 mg after having received approval from the US Food and Drug Administration (USFDA), Lupin said in a regulatory filing.

The Mumbai-based company's product is the generic version of Valeant Pharmaceuticals International Inc's Ancobon tablets.

The drug is indicated for the treatment of serious infections.

According to the latest IMS sales data, Flucytosine capsules have annual sales of around $48 million in the US.

Lupin shares were trading 2.47 per cent up at Rs 899.15 apiece on BSE on Friday.

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel